← Back to Search

Aldehyde Dehydrogenase Inhibitor

Disulfiram for Retinal Degeneration

Phase 1 & 2

Recruiting

Led By Debarshi Mustafi, MD, PhD

Research Sponsored by University of Washington

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up year 1

Awards & highlights

Study Summary

This trial showed that a drug that blocks a certain pathway in the eye led to improved vision in a mouse model of inherited retinal diseases.

Who is the study for?

Adults over 18 with a clinical diagnosis of inherited retinal degeneration, who have relatively good vision (20/40 or better) and can see within 10 degrees centrally. Participants must not drink alcohol for the duration of the study plus two weeks before and after. They should also have normal levels of albumin, total protein, ALT, AST, and ALP.Check my eligibility

What is being tested?

The trial is testing Disulfiram (250 mg), an FDA-approved drug that may improve visual function by inhibiting a pathway linked to vision loss in retinal degeneration. It's compared against a placebo to evaluate its effectiveness in humans.See study design

What are the potential side effects?

Disulfiram can cause side effects such as headaches, fatigue, skin rash or acne; more rarely it might lead to liver problems or neurological changes.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ year 1

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~year 1

This trial's timeline: 3 weeks for screening, Varies for treatment, and year 1 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Assess the effects of disulfiram on retinal sensitivity in eyes afflicted with inherited retinal degenerations

Secondary outcome measures

Assess the effects of disulfiram on photoreceptor functionality in eyes afflicted with inherited retinal degenerations.

Assess the effects of disulfiram on visual acuity in eyes afflicted with inherited retinal degenerations.

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: DisulfiramActive Control1 Intervention

Disulfiram medication

Group II: PlaceboPlacebo Group1 Intervention

Placebo medication

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of WashingtonLead Sponsor

1,741 Previous Clinical Trials

1,847,736 Total Patients Enrolled

1 Trials studying Retinitis Pigmentosa

438 Patients Enrolled for Retinitis Pigmentosa

Debarshi Mustafi, MD, PhDPrincipal InvestigatorUniversity of Washington

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many individuals are enlisted in this clinical experiment?

"Affirmative. Data hosted on clinicaltrials.gov suggests that this medical trial is actively seeking participants, with the initial post date being 12/1/2023 and its most recent edit occurring 11/29/2023. The study requires 30 patients to be recruited from a single site."

Answered by AI

Is this research project actively seeking participants?

"Affirmative. Per the details on clinicaltrials.gov, this examination is actively searching for participants with a post date of December 1st 2023 and latest modification made on November 29th 2023. The research requires 30 candidates to be enrolled at one medical centre."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Disulfiram for Treatment of Retinal Degeneration

Debarshi Mustafi 2023. "Disulfiram for Treatment of Retinal Degeneration". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05626920.

All > Retinitis Pigmentosa